On Tuesday, Shares of The Coca-Cola Company (NYSE:KO), lost -1.45% to $38.75.
Coke Zero™ is bringing its first-of-its-kind drinkable marketing campaign to the football field, giving fans a chance to try delicious and refreshing zero-calorie Coke Zero through multiple innovative avenues. This season, Coke Zero is expanding the “You Don’t Know Zero ‘Til You’ve Tried It”™ campaign through a fully integrated drinkable campaign using multiple broadcast spots, traditional media, digital, out-of-home, retail, social media engagement and the most popular pre-game show on television — ESPN’s College GameDay Built by The Home Depot.
To kick off the third year of its partnership with ESPN College GameDay, Coke Zero is returning to college football with Section Zero — now, a Saturday staple, and the most coveted seat for the ultimate fan. At each campus ESPN College GameDay visits, Section Zero will treat 50 fans to premium seating and a chance to see ESPN College GameDay’s newest cast member, Rece Davis! Students can gain access to Section Zero by showing their school spirit on game day and participating in a few classic tailgate games on campus. Those fans not on campus can experience the fun of Section Zero by tuning in to the show nationwide, or by following @CokeZero on Twitter and Instagram.
The Coca-Cola Company, a beverage company, manufactures and distributes various nonalcoholic beverages worldwide. The company primarily offers sparkling beverages and still beverages. Its sparkling beverages comprise nonalcoholic ready-to-drink beverages with carbonation, such as carbonated energy drinks, and carbonated waters and flavored waters.
Shares of Exelixis, Inc. (NASDAQ:EXEL), declined -5.88% to $5.60, during its last trading session.
Exelixis declared that Swissmedic, the Swiss licensing and supervisory authority of Switzerland, has approved cobimetinib for use in combination with vemurafenib as a treatment for patients with advanced melanoma. Cobimetinib is a selective inhibitor of MEK that was discovered by Exelixis and is the subject of a worldwide partnershipagreement between Exelixis and Genentech, a member of the Roche Group. The trade name for cobimetinib in Switzerland is Cotellic™.
Roche’s Swiss regulatory submission for cobimetinib was based on data from coBRIM, the phase 3 pivotal trial of cobimetinib and vemurafenib conducted in 495 patients with formerly untreated unresectable, locally advanced or metastatic melanoma with a BRAF V600 mutation. The resulting approval is the first for cobimetinib worldwide, and additional regulatory applications are under review in other territories. Genentech filed its New Drug Application (NDA) for cobimetinib with the U.S. Food and Drug Administration (FDA) in December 2014 and the Prescription Drug User Fee Act date is November 11, 2015. Separately, Roche filed a Marketing Authorization Application with the European Medicines Agency in late 2014, and Roche anticipates a regulatory decision before the end of 2015.
Exelixis, Inc., a biopharmaceutical company, develops and sells small molecule therapies for the treatment of cancer in the United States. The company offers COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer.
Finally, Nevro Corp. (NYSE:NVRO), ended its last trade with 0.09% gain, and closed at $45.07.
Nevro Corp., declared that the company has presented its preliminary response to the Patent Trial and Appeals Board (PTAB) in response to two petitions for inter partes review (IPR), filed by a unit of Boston Scientific Corporation, challenging the validity of certain claims in U.S. Patent No. 8,359,102 (the ‘102 patent). The ‘102 patent is one of Nevro’s 55 issued U.S. patents directed to Nevro’s innovations in the neuromodulation field.
The preliminary response is limited in scope by the rules governing the IPR process. The response is limited to setting forth the reasons why an IPR should not be instituted and cannot argue the merits or comprise any new testimonial evidence.
Nevro Corp., a medical device company, develops and commercializes a neuromodulation platform for the treatment of chronic pain. It offers Senza system, a spinal cord stimulation system that delivers its proprietary HF10 therapy. The company was founded in 2006 and is headquartered in Menlo Park, California.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
